Sodium‐glucose co‐transporter 2 inhibitors reduce the intravitreal anti‐ VEGF treatment necessity in eyes with early diabetic macular oedema: A post‐hoc analysis focusing on the fellow eye of the COMET trial
Authors' conclusion
Systemic SGLT2i therapy reduced the need for intravitreal anti-VEGF treatment in eyes with early and mild DMO. These results suggest that SGLT2i may be effective in preventing the progression of early and mild DMO.
Study context
- Population
- Fellow eyes with no or mild macular oedema at baseline in patients with DME eligible for anti-VEGF therapy; Intravitreal ranibizumab (IVR) per protocol to both eyes over 48 weekspatients randomized
- Participants
- 60 participants
- Comparison
- SGLT2i luseogliflozin vs sulfonylurea (SU) glimepiride
- SGLT2in = 22 eyes
- SUn = 20 eyesreference
Methodological detailsprospective, randomized, parallel, investigator-driven
- Prospective
- Randomized
- Parallel
- Investigator-driven
Primary result
As reported in the abstract
IVR required · 48 weeks
SGLT2i
2 of 22 eyes
2 of 22 eyes
SU
9 of 20 eyes
9 of 20 eyes
Further findings
- Changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) did not differ significantly between groups
Original publication
Sodium‐glucose co‐transporter 2 inhibitors reduce the intravitreal anti‐ VEGF treatment necessity in eyes with early diabetic macular oedema: A post‐hoc analysis focusing on the fellow eye of the COMET trial. Diabetes Obes Metab. Published 4 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →